Lempo Therapeutics

Company Overview

Snapshot

Founded in December 2017 by Oren Glanz and Prof. Ben-Zion Garty, Lempo Therapeutics operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing novel gene-editing treatments.

Business overview

Lempo Therapeutics is a preclinical biotech company specializing in gene editing to modify the immune system for the attenuation of severe chronic diseases. The company's core technology involves a patented ex vivo stem cell gene-editing technique designed to minimize collateral damage from immune system activity, thereby mitigating disease progression. Initially, Lempo Therapeutics is targeting pulmonary arterial hypertension (PAH), a rare cardiovascular disease, but its concept has shown effectiveness in animal models for conditions such as Alzheimer's disease, multiple sclerosis, and other cardiovascular diseases. The company operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.

Company Intelligence Q&A

What is Lempo Therapeutics' primary focus?

Lempo Therapeutics focuses on using gene editing to modify the immune system for attenuating severe chronic diseases, with an initial focus on pulmonary arterial hypertension (PAH).

When was Lempo Therapeutics founded?

Lempo Therapeutics was founded in December 2017.

Who are the founders of Lempo Therapeutics?

Lempo Therapeutics was co-founded by Oren Glanz and Prof. Ben-Zion Garty.

What is the core technology used by Lempo Therapeutics?

The company utilizes a novel, patented ex vivo stem cell gene-editing technique to minimize immune system-induced collateral damage and mitigate disease progression.

In which sector does Lempo Therapeutics primarily operate?

Lempo Therapeutics operates primarily in the Health Tech & Life Sciences sector, specifically within Pharma & Medical Biotechnology and Drugs Discovery & Development.